GeneDx Holdings Corp (NASDAQ: WGS) on Monday, plunged -11.92% from the previous trading day, before settling in for the closing price of $135.38. Within the past 52 weeks, WGS’s price has moved between $55.17 and $170.87.
Healthcare Sector giant saw their annual sales surged by 96.65% over the last five years. The company achieved an average annual earnings per share of 429.88%. With a float of $25.35 million, this company’s outstanding shares have now reached $28.89 million.
GeneDx Holdings Corp (WGS) Breakdown of a Key Holders of the stock
Observing investor behavior towards Diagnostics & Research industry stocks is more important than anything else. The insider ownership of GeneDx Holdings Corp is 12.28%, while institutional ownership is 104.61%. The most recent insider transaction that took place on Dec 16 ’25, was worth 554,616. In this transaction CHIEF FINANCIAL OFFICER of this company sold 3,855 shares at a rate of $143.87, taking the stock ownership to the 8,731 shares. Before that another transaction happened on Dec 16 ’25, when Company’s CHIEF EXECUTIVE OFFICER sold 10,857 for $143.89, making the entire transaction worth $1,562,185. This insider now owns 14,237 shares in total.
GeneDx Holdings Corp (WGS) Recent Fiscal highlights
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported 0.64 earnings per share (EPS) for the period topping the consensus outlook (set at 0.1) by 0.53. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 429.88% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 87.18% during the next five years compared to 96.65% growth over the previous five years of trading.
GeneDx Holdings Corp (NASDAQ: WGS) Trading Performance Indicators
GeneDx Holdings Corp (WGS) is currently performing well based on its current performance indicators. A quick ratio of 2.59 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.57. Likewise, its price to free cash flow for the trailing twelve months is 222.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.06, a number that is poised to hit 0.09 in the next quarter and is forecasted to reach 0.45 in one year’s time.
